AUROBAC THERAPEUTICS
AUROBAC THERAPEUTICS is a clinical-stage biopharmaceutical company developing precision medicines to fight antimicrobial resistance, with a lead host-targeted sepsis program (ATX101) partnered with Boehringer Ingelheim. Founded in 2022 by Boehringer Ingelheim, Evotec, and bioMérieux and headquartered in Lyon, the company targets hospitals and intensive care units treating severe bacterial infections, HAP/VAP, sepsis, and septic shock.
- Company typePrivate
- Founded2022
- HeadquartersLyon, France
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
AUROBAC THERAPEUTICS firmographics
Firmographics- Name
- AUROBAC THERAPEUTICS
- Legal name
- AUROBAC THERAPEUTICS SAS
- Website
- https://aurobac-tx.com
- Company type
- Private
- Founded year
- 2022
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- AUROBAC THERAPEUTICS is a clinical-stage biopharmaceutical company developing precision medicines to fight antimicrobial resistance, with a lead host-targeted sepsis program (ATX101) partnered with Boehringer Ingelheim. Founded in 2022 by Boehringer Ingelheim, Evotec, and bioMérieux and headquartered in Lyon, the company targets hospitals and intensive care units treating severe bacterial infections, HAP/VAP, sepsis, and septic shock.
- Ownership category
- akta.pro rank
AUROBAC THERAPEUTICS industry classification
Industry- Product category
- Anti-Infective Therapeutics
- NAICS
- Scientific Research and Development Services (5417)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG)
- akta.pro secondary industries
- Infectious Disease Specialty Pharmaceuticals (Non-vaccine) (HLAIACAM), Regulatory Strategy & IND/NDA/BLA Submissions Support (HLAIALAH), Genomics & Molecular Diagnostics (Trial Support) (HLAGAEAD)
Keywords
Where AUROBAC THERAPEUTICS is headquartered
LocationHeadquarters
- HQ city
- Lyon
- HQ country
- France
- HQ region
- Europe
Offices4 records
Markets served
AUROBAC THERAPEUTICS business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Pharmaceutical Product Sales: As a biopharmaceutical company developing novel drugs, AUROBAC's primary expected revenue stream will come from commercialization of pipeline products (ATX101, ATX5) for treatment of sepsis, septic shock, and Gram-negative bacterial infections. The company aims to cover the entire value chain from research and development through clinical trials, registration, and commercialization.
- Licensing and Partnership Agreements: AUROBAC pursues various partnership agreements including R&D consortiums, academic cooperation, co-development arrangements, licensing agreements, and potential full acquisitions. The company leverages support from founding organizations (Boehringer Ingelheim, bioMérieux, Evotec) to bring innovative products to market.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
AUROBAC THERAPEUTICS product offering
Product offeringCore offering
AUROBAC THERAPEUTICS develops novel chemical entities — led by ATX101 (a first-in-class host-targeted treatment for sepsis and septic shock that completed Phase 1 in March 2026) and ATX5 (a discovery-stage program against Gram-negative pathogens) — that address both the causes and consequences of severe bacterial infections and antimicrobial resistance in acute hospital settings. The pipeline is supported by a Drug Discovery Engine and a diagnostic-driven precision medicine strategy pairing therapeutics with rapid patient-stratification diagnostics.
Product overview
AUROBAC THERAPEUTICS is a biopharmaceutical company developing a pipeline of precision medicines targeting severe bacterial infections and antimicrobial resistance (AMR). The product portfolio consists of ATX101 (a first-in-class host-targeted new chemical entity for sepsis and septic shock, partnered with Boehringer Ingelheim, currently in Phase 1 completed), ATX5 (a MedChem program for Gram-negative pathogens in hit-to-lead stage), and a Drug Discovery Engine that integrates strategic partnerships to identify novel antimicrobial agents. The company focuses on patient- and pathogen-targeted programs for hospital-acquired infections, ventilator-associated pneumonia, and sepsis.
Differentiator
Problem solved
Functional benefit
Products and services
- ATX101 First-in-class host-targeted new chemical entity designed to address the pathophysiological mechanisms of sepsis and septic shock, with the target indication being treatment of early septic shock to prevent progression and improve outcomes. Partnered with Boehringer Ingelheim.
- ATX5 New chemical entity in a MedChem program targeting an undisclosed mechanism for the treatment of infections caused by Gram-negative pathogens. Currently in hit-to-lead stage as part of AUROBAC's Drug Discovery Engine hit discovery programs.
Quantifiable outcome
- Phase 1 clinical trial successfully completed for ATX101 in March 2026 (ClinicalTrials.gov NCT07107802)
- +2 more outcomes
Companies that use AUROBAC THERAPEUTICS
Customer profileSegments3 records
Ideal customer profiles2 records
AUROBAC THERAPEUTICS technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
AUROBAC THERAPEUTICS partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered founding/core and minor.
- Boehringer Ingelheimfounding/coreNew collaboration and license agreement on a Boehringer Ingelheim compound developed as ATX101 for treatment of septic shock. The strategic partnership with Boehringer Ingelheim reflects 'shared commitment to developing innovative therapies to tackle urgent unmet medical needs in patients in critical care settings.' Phase 1 trial completion (March 2026) 'reflects the strength of its strategic partnership with Boehringer Ingelheim.'
- Boehringer Ingelheimfounding/coreBoehringer Ingelheim is a founding organization of AUROBAC THERAPEUTICS (established 2022). The partnership includes collaboration on ATX101 development - Boehringer Ingelheim contributed a compound licensed to AUROBAC for septic shock treatment development. AUROBAC's headquarters is located within Boehringer Ingelheim's building in Lyon. Frank Kalkbrenner represented Boehringer Ingelheim as former Chairman of the Board. ATX101 clinical trial collaboration mentioned as 'strong and productive collaboration with Boehringer Ingelheim' for developing innovative therapies for critical care settings.
- bioMérieuxfounding/corebioMérieux is a founding organization of AUROBAC THERAPEUTICS (established 2022). The company brings diagnostic capabilities supporting AUROBAC's diagnostic-driven precision medicine strategy. François Lacoste, DVM represents bioMérieux on AUROBAC's Board of Directors. The combination of pharma (Boehringer Ingelheim), diagnostics (bioMérieux), and drug discovery (Evotec) capabilities forms the foundation of AUROBAC's strategic approach.
- Evotec SEfounding/coreEvotec is a founding organization of AUROBAC THERAPEUTICS (established 2022). The company provides drug discovery capabilities including the 'Drug Discovery Engine' that integrates strategic partnerships to efficiently identify and advance novel antimicrobial agents. Antonio Felici, Ph.D. represents Evotec on AUROBAC's Board of Directors.
- BEAM AllianceminorAUROBAC THERAPEUTICS is a member of the BEAM Alliance (Biomedicines for Antimicrobial Resistance). BEAM Alliance is a European alliance of companies developing antimicrobials, antibiotics, alternatives to antibiotics, and diagnostics for human health. CEO Florence Séjourné represents AUROBAC and BEAM Alliance at industry events including World Health Summit 2024.
Scale indicators7 records
Recent moves7 records
Expansion highlights6 records
AUROBAC THERAPEUTICS competitors and assessment
Company assessmentDirect peers
- BioVersys: Swiss clinical-stage biopharmaceutical company developing small molecule drugs to fight antimicrobial resistance, with a focus on hospital-acquired infections and ESKAPE pathogens. Directly comparable as a European AMR-focused biotech with similar therapeutic focus, pipeline stage, and BEAM Alliance membership.
- Entasis Therapeutics: Clinical-stage biopharmaceutical company developing targeted therapies for drug-resistant bacterial infections, including Gram-negative pathogens. Highly comparable focus on AMR, precision medicine approaches, and similar development stage; acquired by Innoviva in 2022.
- Iterum Therapeutics: Clinical-stage pharmaceutical company developing antibiotics against multi-drug resistant pathogens, with focus on Gram-negative infections and oral and IV antibiotics. Directly comparable as a clinical-stage anti-infective company targeting similar pathogens and hospital-acquired infections.
- Cidara Therapeutics: Clinical-stage biotechnology company developing novel anti-infectives including immunotherapies for serious infections. Comparable as a clinical-stage anti-infective biotech targeting serious bacterial and fungal infections in hospital settings.
- Melinta Therapeutics: Commercial-stage pharmaceutical company focused on developing and commercializing novel antibiotics to treat serious bacterial infections. Comparable as an antibiotics-focused company targeting multi-drug resistant infections in hospital settings; emerged from bankruptcy in 2020.
- Paratek Pharmaceuticals: Commercial-stage biopharmaceutical company developing and commercializing novel antibiotics for serious community-acquired and hospital-acquired bacterial infections. Comparable focus on antibacterial innovation and similar therapeutic indications including pneumonia; acquired by Gurnet Point in 2023.
- VenatoRx Pharmaceuticals: Private clinical-stage pharmaceutical company developing novel therapies to treat drug-resistant bacterial infections, particularly Gram-negative ESKAPE pathogens. Comparable as a clinical-stage antibiotics developer targeting multi-drug resistant Gram-negative infections.
- Tetraphase Biosciences: Biopharmaceutical company (acquired by La Jolla Pharmaceutical in 2020) that developed XERAVA, a novel antibiotic for complicated intra-abdominal infections caused by resistant bacteria. Comparable antibiotics developer with focus on multi-drug resistant bacterial infections.
Broad incumbents
- Innoviva (Entasis parent): Diversified specialty pharmaceutical company that acquired Entasis Therapeutics in 2022 to add a clinical-stage anti-infective franchise targeting AMR. Comparable through its anti-infective subsidiary addressing drug-resistant infections.
- Shionogi: Japanese pharmaceutical company with a strong anti-infectives franchise including cefiderocol (FETROJA), an antibiotic targeting multi-drug resistant Gram-negative infections including those causing HAP/VAP and sepsis. Comparable through its late-stage antibacterial portfolio addressing AMR in hospital settings.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
AUROBAC THERAPEUTICS social profiles
Digital presenceAUROBAC THERAPEUTICS financial estimates
Financial estimateRevenue estimate
Valuation estimate
AUROBAC THERAPEUTICS leadership team
Management profileNumber of profiles
Profiles9 records
AUROBAC THERAPEUTICS subsidiaries and ownership
Company hierarchySubsidiaries2 records
AUROBAC THERAPEUTICS funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
AUROBAC THERAPEUTICS M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about AUROBAC THERAPEUTICS
What does AUROBAC THERAPEUTICS do?
AUROBAC THERAPEUTICS develops novel chemical entities — led by ATX101 (a first-in-class host-targeted treatment for sepsis and septic shock that completed Phase 1 in March 2026) and ATX5 (a discovery-stage program against Gram-negative pathogens) — that address both the causes and consequences of severe bacterial infections and antimicrobial resistance in acute hospital settings. The pipeline is supported by a Drug Discovery Engine and a diagnostic-driven precision medicine strategy pairing therapeutics with rapid patient-stratification diagnostics.
Is AUROBAC THERAPEUTICS a public or private company?
AUROBAC THERAPEUTICS is a private company. It is classified as corporate owned and is currently operating.
When was AUROBAC THERAPEUTICS founded?
AUROBAC THERAPEUTICS was founded in 2022. It employs 11 to 50 people.
Where is AUROBAC THERAPEUTICS based?
AUROBAC THERAPEUTICS is headquartered in Lyon, France, in the Europe region.
How does AUROBAC THERAPEUTICS make money?
Two revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are licensing and Partnership Agreements.
Who are AUROBAC THERAPEUTICS's main competitors?
Direct peers on record are BioVersys, Entasis Therapeutics, Iterum Therapeutics, Cidara Therapeutics, Melinta Therapeutics, Paratek Pharmaceuticals, VenatoRx Pharmaceuticals and Tetraphase Biosciences. Broad incumbents are Innoviva (Entasis parent) and Shionogi.
Does AUROBAC THERAPEUTICS have an API?
No public API is recorded for AUROBAC THERAPEUTICS.
What industry is AUROBAC THERAPEUTICS in?
AUROBAC THERAPEUTICS's product category is Anti-Infective Therapeutics. Its primary akta.pro industry code is HLAIAAAG, Infectious Disease & Antimicrobials Pharmaceuticals, with a secondary code of HLAIACAM, Infectious Disease Specialty Pharmaceuticals (Non-vaccine). Its NAICS code is 5417 and its SIC code is 2836.